MET and Alzheimer disease: Consistent with the posited neuroprotective role of MET signaling in AD, recent clinical literature demonstrated reduced levels of MET protein in the cerebral cortex and hippocampus of patients with AD (Hamasaki et al., 2014; Matsumoto et al., 2014).